Report
Description
Report Description
Request for sample report: http://www.futuremarketinsights.com/reports/sample/repgb-1763
The drivers for dengue vaccine market include growing healthcare concerns, increase in
mortality rate because of dengue fever. And the challenges faced by the scientist in
developing this vaccines were majorly due to the complexity of the dengue virus,
expensive trials and time to develop them. After the introduction of Dengvaxia (CYDTDV), five additional candidates are I clinical trials. The prices for dengue vaccines are
much higher but due to government intervention the vaccine are sold on discounted
prices in most countries. In March 2016, Dengvaxia was licensed in Mexico, the
Philippines, Brazil and El Salvador for effective prevention against dengue from all four
serotypes which are mostly found in individuals of age 9-45 years living in endemic areas.
According to WHO (World Health Organization) dengue epidemics are being reported
every year from more than 100 endemic countries causing 50-100 million dengue
infections worldwide annually. In the years 2010, 2013 and 2015, nearly 2.4 million cases
of dengue had been reported indicating the sharp increase in the number. It was
estimated 500 000 people with severe dengue require hospitalization each year and from
them 2.5% of those affected die each year. The dengue vaccine is being produced in in
France in dedicated manufacturing site including a full-scale production capacity of 100
million of vaccine doses annually.